{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:22:29Z","timestamp":1766269349575,"version":"3.37.3"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T00:00:00Z","timestamp":1471996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>A meta-analysis reported an 8% increased risk of cancer with the use of angiotensin receptor blockers (ARBs), but subsequent meta-analyses and observational studies did not confirm this risk. However, telmisartan comprised 85% of the data in the original meta-analysis. Thus, the objective of this study was to determine whether the use of telmisartan, compared with other ARBs, is associated with an increased risk of cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We used the United Kingdom Clinical Practice Research Datalink to assemble a cohort of all patients newly treated with ARBs between 2000 and 2008, and followed until December 2010. Time-dependent cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of cancer associated with telmisartan, compared with other ARBs, adjusted for potential confounders. Secondary analyses assessed the risk with each of the 4 most common cancers (lung, breast, prostate, colorectal).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>The cohort consisted of 62,109 new ARB users, which included 3,438 telmisartan and 58,671 other ARB users. Compared with other ARBs, telmisartan use was not associated with an increased risk of cancer overall (16.3 vs. 15.0 per 1,000 person-years, respectively; adjusted HR: 0.93, 95% CI: 0.81\u20131.06) or by cancer site (lung, HR: 0.91, 95% CI: 0.55\u20131.51; breast, HR: 1.28, 95% CI: 0.90\u20131.82; prostate, HR: 0.79, 95% CI: 0.53\u20131.18; colorectal, HR: 1.41, 95% CI 0.95\u20132.10).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Compared with other ARBs, telmisartan is not associated with an increased risk of cancer. This study provides reassurance as to the short-term safety of telmisartan.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpw095","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T00:58:35Z","timestamp":1472086715000},"page":"1358-1365","source":"Crossref","is-referenced-by-count":15,"title":["The Use of Telmisartan and the Incidence of Cancer"],"prefix":"10.1093","volume":"29","author":[{"given":"Koray","family":"Tascilar","sequence":"first","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital 1 , Montreal, Quebec , Canada ;"},{"name":"Department of Internal Medicine, Division of Rheumatology, Istanbul University Cerrahpasa Faculty of Medicine 2 , Istanbul , Turkey ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Azoulay","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital 1 , Montreal, Quebec , Canada ;"},{"name":"Department of Oncology, McGill University 3 , Montreal, Quebec , Canada ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Dell\u2019Aniello","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital 1 , Montreal, Quebec , Canada ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee B.","family":"Bartels","sequence":"additional","affiliation":[{"name":"Department of Global Epidemiology, Boehringer Ingelheim GmbH 4 , Ingelheim , Germany ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samy","family":"Suissa","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital 1 , Montreal, Quebec , Canada ;"},{"name":"Department of Epidemiology, Biostatistics and Occupational Health, McGill University 5 , Montreal, Quebec , Canada ."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,8,24]]},"reference":[{"key":"2024020111110796100_CIT0001","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol"},{"key":"2024020111110796100_CIT0002","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"Lancet Oncol"},{"key":"2024020111110796100_CIT0003","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","article-title":"Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals","volume":"29","author":"ARB Trialists Collaboration","year":"2011","journal-title":"J Hypertens"},{"author":"FDA","key":"2024020111110796100_CIT0004"},{"key":"2024020111110796100_CIT0005","doi-asserted-by":"crossref","first-page":"e50893","DOI":"10.1371\/journal.pone.0050893","article-title":"Long-term use of angiotensin receptor blockers and the risk of cancer","volume":"7","author":"Azoulay","year":"2012","journal-title":"PLoS One"},{"key":"2024020111110796100_CIT0006","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04170.x","article-title":"Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study","volume":"74","author":"Hallas","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"2024020111110796100_CIT0007","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.amjcard.2010.11.026","article-title":"Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension","volume":"107","author":"Huang","year":"2011","journal-title":"Am J Cardiol"},{"key":"2024020111110796100_CIT0008","doi-asserted-by":"crossref","first-page":"e2697","DOI":"10.1136\/bmj.e2697","article-title":"Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database","volume":"344","author":"Bhaskaran","year":"2012","journal-title":"BMJ"},{"key":"2024020111110796100_CIT0009","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2011.35.1908","article-title":"Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study","volume":"29","author":"Chang","year":"2011","journal-title":"J Clin Oncol"},{"key":"2024020111110796100_CIT0010","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.110.007336","article-title":"Use of angiotensin receptor blockers and the risk of cancer","volume":"123","author":"Pasternak","year":"2011","journal-title":"Circulation"},{"key":"2024020111110796100_CIT0011","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/2042098611435911","article-title":"Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource","volume":"3","author":"Williams","year":"2012","journal-title":"Ther Adv Drug Saf"},{"key":"2024020111110796100_CIT0012","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","article-title":"Validation and validity of diagnoses in the General Practice Research Database: a systematic review","volume":"69","author":"Herrett","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"2024020111110796100_CIT0013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jch.12228","article-title":"Lowered cancer risk with ACE inhibitors\/ARBs: a population-based cohort study","volume":"16","author":"Chiang","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2024020111110796100_CIT0014","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.amjcard.2011.06.031","article-title":"Immortal person time bias in pharmacoepidemiological studies of antihypertensive drugs","volume":"108","author":"Assimes","year":"2011","journal-title":"Am J Cardiol"},{"key":"2024020111110796100_CIT0015","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"2024020111110796100_CIT0016","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"2024020111110796100_CIT0017","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"key":"2024020111110796100_CIT0018","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article\/29\/12\/1358\/2708298","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article\/29\/12\/1358\/2708298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T11:11:44Z","timestamp":1706785904000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/29\/12\/1358\/2708298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,24]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,8,24]]},"published-print":{"date-parts":[[2016,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpw095","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"type":"print","value":"0895-7061"},{"type":"electronic","value":"1941-7225"}],"subject":[],"published":{"date-parts":[[2016,8,24]]}}}